Immutep's IMP761 Shows Positive Data in Phase I Study
Immutep Limited announced positive data from its Phase I study of IMP761, a LAG-3 agonist antibody, presented at ACR Convergence 2026. The study showed statistically significant and exposure-dependent inhibition of T-cell-driven immune responses in healthy volunteers, with the drug being well-tolerated. The pharmacokinetic profile supports a four-week dosing interval, and the ongoing multiple ascending dose portion has shown no new safety signals. Complementary pre-clinical studies also indicated potential for IMP761 in autoimmune diseases. Results from the MAD portion are expected in H1 CY2027.
Key Highlights
- IMP761 demonstrated statistically significant and exposure-dependent inhibition of T-cell-driven immune responses in healthy volunteers.
- The drug was well tolerated across all seven dose levels, with a pharmacokinetic profile supporting a four-week dosing interval.
- The multiple ascending dose (MAD) portion of the Phase I study is ongoing, with no new safety signals observed.
- Pre-clinical studies in rheumatoid arthritis patients showed IMP761 reduced T-cell activation and proliferation.
- Results from the MAD portion of the study are anticipated in H1 CY2027 to inform dose selection for a potential Phase II program.
Price Impact
More from IMMP
Immutep Ltd: EFTISARC-NEO Trial Shows 81.1% DFS at 12 Months in STS Patients
Immutep Q1 FY27: Efti focus shifts, IMP761 gains priority, cash $48.5M
Immutep Q4 FY26 Cash A$68.87M; TACTI-004 Futility Analysis Ongoing